Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has reported its financial results for the first half of 2026, revealing a notable increase in revenue and significant strides in its contract development and manufacturing organization (CDMO) operations. The company, which combines therapeutic development with a revenue-generating CDMO business, announced revenue of $949,000 for the period, up from $773,000 in the prior-year period. This growth is complemented by committed customer orders of approximately $3.1 million as of Aug. 16, 2026, including about $2.1 million already invoiced.
In a strategic move, Scinai is advancing an expanded clinical manufacturing and chemistry, manufacturing, and controls (CMC) program for a U.S.-based biopharmaceutical company. The company has received approximately $650,000 in cash payments and advances for this program, with substantive activities already underway while a definitive agreement is being negotiated. This program is designed to support an investigational drug product toward a U.S. investigational new drug (IND) submission and Phase III clinical development. This initiative underscores Scinai's commitment to expanding its CDMO footprint and capitalizing on its manufacturing capabilities.
The company's financial performance for the first half also included an operating loss of approximately $4.6 million, compared to $3.8 million in the same period last year. However, net income swung to a positive $1.6 million, a significant improvement from a net loss of $4.1 million in the prior-year period. This turnaround was primarily driven by a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. As of June 30, 2026, Scinai held cash, cash equivalents, and restricted cash totaling approximately $2.9 million.
Scinai continues to pursue approximately $5 million in CDMO revenue for 2026, reflecting its strategic emphasis on growing its service-based revenue stream. The company is also advancing its therapeutic programs, including PC111 and NanoAbs, which are part of its pipeline of innovative immunology therapies licensed from the Max Planck Society and PinCell S.r.l.
The company will host an investor webinar on Aug. 26, 2026, to discuss recent developments, financial performance, and upcoming milestones. This webinar is expected to provide further insights into Scinai's strategic direction and operational progress.
Scinai's dual focus on therapeutic development and CDMO services positions it uniquely in the biopharmaceutical landscape. By leveraging its facilities in Jerusalem and Yavne, Israel, the company aims to provide development and manufacturing services to biotechnology and pharmaceutical companies, thereby generating revenue while advancing its own pipeline.
The expansion of the U.S. clinical manufacturing program is a key indicator of Scinai's growth trajectory. With a definitive agreement still under negotiation, the company is already receiving payments and advancing activities, demonstrating the trust and interest from its clients. This program is expected to play a pivotal role in supporting a client's investigational drug product through regulatory milestones.
Investors and stakeholders will be watching closely as Scinai continues to execute on its strategic plan. The company's ability to secure orders and advance its CDMO operations will be critical to achieving its revenue targets and sustaining growth. The recent financial results and operational milestones suggest a positive momentum, though challenges remain, including managing operating losses and maintaining adequate cash reserves.
For more information, visit the company's newsroom at https://nnw.fm/SCNI.
This announcement reflects Scinai's ongoing efforts to integrate its therapeutic development with a viable commercial manufacturing business, a strategy that could enhance its long-term value proposition in the competitive biopharmaceutical market.
